US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

This discovery marks a significant step forward in understanding myositis and opens new avenues for treatment and management ...

“C-protein-induced myositis [CIM] is much more like human ... mononuclear cell infiltration first became evident, anti-IL-6 treatment alleviated disease. “Although IL-6 blockade abrogated ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Inclusion Body Myositis- Features asymmetric muscle weakness ... She is recognized for her contributions to advancing treatment options and understanding of these challenging conditions.

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated with ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Learn about dermatomyositis and the remarkable journey of Audrey Gouskos. Discover how St. Michael's Hospital has provided ...